Compare Stocks: OPT, ZYME, NBTX, and VCEL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NBTX Nanobiotix	$38.80 -3.0%	$39.72	$8.28 ▼ $57.14	$1.96B	0.81	176,718 shs	119,295 shs
OPT Opthea	$3.41	$3.41	$1.79 ▼ $6.30	$524.84M	1.12	N/A	N/A
VCEL Vericel	$40.19 -0.7%	$44.72	$28.95 ▼ $49.32	$2.06B	1.04	483,593 shs	312,911 shs
ZYME Zymeworks	$29.19 -2.4%	$25.54	$14.06 ▼ $31.34	$2.07B	1.19	738,808 shs	476,597 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NBTX Nanobiotix	-3.00%	-5.89%	-2.19%	+9.42%	+348.81%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	0.00%
VCEL Vericel	-0.69%	-1.86%	-11.40%	+10.72%	+19.79%
ZYME Zymeworks	-2.37%	+3.25%	+24.21%	+21.42%	+106.44%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NBTX Nanobiotix	$38.80 -3.0%	$39.72	$8.28 ▼ $57.14	$1.96B	0.81	176,718 shs	119,295 shs
OPT Opthea	$3.41	$3.41	$1.79 ▼ $6.30	$524.84M	1.12	N/A	N/A
VCEL Vericel	$40.19 -0.7%	$44.72	$28.95 ▼ $49.32	$2.06B	1.04	483,593 shs	312,911 shs
ZYME Zymeworks	$29.19 -2.4%	$25.54	$14.06 ▼ $31.34	$2.07B	1.19	738,808 shs	476,597 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NBTX Nanobiotix	-3.00%	-5.89%	-2.19%	+9.42%	+348.81%
OPT Opthea	0.00%	0.00%	0.00%	0.00%	0.00%
VCEL Vericel	-0.69%	-1.86%	-11.40%	+10.72%	+19.79%
ZYME Zymeworks	-2.37%	+3.25%	+24.21%	+21.42%	+106.44%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NBTX Nanobiotix	2.50	Moderate Buy	$37.33	-3.78% Downside
OPT Opthea	1.00	Sell	N/A	N/A
VCEL Vericel	2.57	Moderate Buy	$58.40	45.31% Upside
ZYME Zymeworks	2.73	Moderate Buy	$41.00	40.46% Upside

Current Analyst Ratings Breakdown

Latest OPT, ZYME, NBTX, and VCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	ZYME Zymeworks	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$31.00 ➝ $33.00
8/26/2026	ZYME Zymeworks	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$32.00
8/26/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/26/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/26/2026	ZYME Zymeworks	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$32.00
8/26/2026	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$51.00 ➝ $55.00
8/10/2026	ZYME Zymeworks	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $44.00
8/10/2026	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/7/2026	ZYME Zymeworks	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$46.00
8/7/2026	ZYME Zymeworks	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$37.00 ➝ $40.00
7/31/2026	VCEL Vericel	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NBTX Nanobiotix	$36.87M	53.27	N/A	N/A	($1.97) per share	-19.70
OPT Opthea	$25K	20,993.46	N/A	N/A	($1.31) per share	-2.60
VCEL Vericel	$276.26M	7.45	$0.56 per share	72.35	$7.23 per share	5.56
ZYME Zymeworks	$105.96M	19.55	N/A	N/A	$1.13 per share	25.83

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NBTX Nanobiotix	-$27.11M	N/A	N/A	388.00	N/A	N/A	N/A	N/A	9/29/2026 (Estimated)
OPT Opthea	-$162.79M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	$16.52M	$0.47	85.51	47.85	N/A	7.91%	6.91%	5.02%	11/5/2026 (Estimated)
ZYME Zymeworks	-$81.13M	-$2.02	N/A	59.57	N/A	-405.31%	-72.30%	-37.18%	11/5/2026 (Estimated)

Latest OPT, ZYME, NBTX, and VCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/29/2026	H1 2026	NBTX Nanobiotix	-$0.1479	N/A	N/A	N/A	$27.25 million	N/A
8/7/2026	Q2 2026	ZYME Zymeworks	-$0.5620	-$0.62	-$0.0580	-$0.62	$4.54 million	$3.23 million
7/30/2026	Q2 2026	VCEL Vericel	-$0.0289	$0.04	+$0.0689	$0.04	$72.70 million	$77.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
OPT Opthea	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NBTX Nanobiotix	N/A	1.09	1.09
OPT Opthea	N/A	0.22	0.22
VCEL Vericel	N/A	5.04	4.69
ZYME Zymeworks	N/A	6.32	6.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NBTX Nanobiotix	38.81%
OPT Opthea	55.95%
VCEL Vericel	N/A
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
NBTX Nanobiotix	3.45%
OPT Opthea	3.20%
VCEL Vericel	7.60%
ZYME Zymeworks	33.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NBTX Nanobiotix	100	50.62 million	48.87 million	Not Optionable
OPT Opthea	8	153.91 million	165.53 million	Not Optionable
VCEL Vericel	300	51.21 million	47.32 million	Optionable
ZYME Zymeworks	460	70.96 million	47.18 million	N/A

OPT, ZYME, NBTX, and VCEL Headlines

Recent News About These Companies

Zymeworks (NASDAQ:ZYME) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

September 5 at 2:36 AM | americanbankingnews.com

Zymeworks (NASDAQ:ZYME) Hits New 52-Week High - Still a Buy?

September 4 at 4:01 AM | americanbankingnews.com

Zymeworks stock gains analyst support after FDA cancer therapy approval

September 4 at 3:40 AM | ad-hoc-news.deA

JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00

September 3 at 5:23 PM | marketbeat.com

Zymeworks (NASDAQ:ZYME) Hits New 1-Year High - Time to Buy?

September 2 at 10:59 AM | marketbeat.com

Zymeworks Inc. (NASDAQ:ZYME) Receives $40.75 Average Target Price from Brokerages

August 31, 2026 | americanbankingnews.com

Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME

August 30, 2026 | marketbeat.com

4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc.

August 30, 2026 | marketbeat.com

FY2026 EPS Estimates for Zymeworks Boosted by HC Wainwright

August 30, 2026 | americanbankingnews.com

Zymeworks stock holds near $28.27 as market cap tops $2.01 billion

August 29, 2026 | ad-hoc-news.deA

HC Wainwright Predicts Zymeworks' Q3 Earnings (NASDAQ:ZYME)

August 29, 2026 | americanbankingnews.com

Zymeworks (ZYME), What Is Behind The Renewed Attention?

August 28, 2026 | finance.yahoo.com

FY2026 EPS Estimates for Zymeworks Raised by HC Wainwright

August 28, 2026 | marketbeat.com

Zymeworks (NASDAQ:ZYME) Stock Price Up 11.4% on Analyst Upgrade

August 28, 2026 | americanbankingnews.com

Citigroup Forecasts Strong Price Appreciation for Zymeworks (NASDAQ:ZYME) Stock

August 28, 2026 | americanbankingnews.com

Zymeworks (NASDAQ:ZYME) Earns Market Outperform Rating from Citizens Jmp

August 28, 2026 | americanbankingnews.com

Zymeworks Inc.: U.S. FDA Approves Ziihera (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma

August 27, 2026 | finanznachrichten.de

HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings

August 27, 2026 | marketbeat.com

Bank of America Corp DE Raises Position in Zymeworks Inc. $ZYME

August 27, 2026 | marketbeat.com

SJM, ZYME stocks hit 52-week high – what’s driving the surge today?

August 26, 2026 | msn.com

JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer

August 26, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OPT, ZYME, NBTX, and VCEL Company Descriptions

Nanobiotix NASDAQ:NBTX

$38.80 -1.20 (-3.00%)

As of 09/4/2026 04:00 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Opthea NASDAQ:OPT

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Vericel NASDAQ:VCEL

$40.19 -0.28 (-0.69%)

As of 09/4/2026 04:00 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Zymeworks NASDAQ:ZYME

$29.19 -0.71 (-2.37%)

As of 09/4/2026 04:00 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OPT, ZYME, NBTX, and VCEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OPT, ZYME, NBTX, and VCEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OPT, ZYME, NBTX, and VCEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OPT, ZYME, NBTX, and VCEL Company Descriptions

Nanobiotix NASDAQ:NBTX

Opthea NASDAQ:OPT

Vericel NASDAQ:VCEL

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OPT, ZYME, NBTX, and VCEL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OPT, ZYME, NBTX, and VCEL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OPT, ZYME, NBTX, and VCEL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OPT, ZYME, NBTX, and VCEL Company Descriptions

Nanobiotix NASDAQ:NBTX

Opthea NASDAQ:OPT

Vericel NASDAQ:VCEL

Zymeworks NASDAQ:ZYME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools